FIG 7.

Broad-spectrum activity of 6940_B01 against clinical envelopes. The activity of 6940_B01 against 124 gp160 variants from 11 subtypes was evaluated in a transient-expression cell-cell fusion assay. Potency is reported as the fold change in EC₅₀ (log scale) relative to the EC₅₀ against gp160 from LAI virus. The solid line for each group indicates the median value. Values greater than 1 indicate a weaker potency (a higher EC₅₀) against a given strain than against LAI. Given the intrinsic assay variability, only fold change values greater than 10 (dashed line) or less than 0.1 were considered significant. Actual fold change values are listed in Table S3 in the supplemental material.